What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Oral and maxillofacial surgery · related questions CL0289

No studies found 1 · 25%GRADE not reported 3 · 75%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Outcome not reported · People with Von Willebrand disease undergoing minor oral surgery or dental extractions

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
No randomised or quasi-randomised controlled trials in people with Von Willebrand disease met the inclusion criteria; no eligible VWD trials were identified.
0 studies
No studies found

Change in haemoglobin level from baseline · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Mean fall in haemoglobin. Forbes (TXA): 1.4 g/100 mL (placebo) vs 0.3 g/100 mL (TXA). Walsh (EACA): 6.3% (placebo, both centres) vs 3.9% and 3.7% (EACA, centres 1 and 2); differences not significant. Reported in…
2 studies · 59 participants
GRADE not reported

Need for and dose of clotting factor concentrates · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Reported in both trials in different ways. Forbes (TXA): mean units of replacement therapy per root extracted 617 IU (range 0 to 15,800) in 11 placebo participants versus 30 IU and 65 IU per root in 2 TXA participants…
2 studies · 59 participants
GRADE not reported

Amount of postoperative blood loss (mL) · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Only reported in the Forbes (TXA) trial: over five-day follow-up, mean blood loss per participant 84.1 mL (range 4 to 323) in the placebo group (n=14) versus 61.2 mL (range 1 to 749) in the TXA group (n=14), P = 0.02.
1 study · 28 participants
GRADE not reported